Ciprofibrate

Ciprofibrate is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha, EC50 = 0.9 µM in a transactivation assay). It is selective for PPARalpha over PPARgamma and PPARdelta at 300 µM. Ciprofibrate (250 µM) induces cell cycle arrest at the G2/M and S phases in Fao rat, but not HepG2 human, hepatocellular carcinoma cells. It decreases fasting plasma levels of triglycerides and increases fasting plasma glucose levels in the apolipoprotein CIII transgenic mouse model of hypertriglyceridemia when administered at a dose of 10 mg/kg. Formulations containing ciprofibrate have been used in the treatment of hypertriglyceridemia.Formal Name: 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-propanoic acid. CAS Number: 52214-84-3. Synonyms: (±)-Ciprofibrate, WIN 35,833. Molecular Formula: C13H14Cl2O3. Formula Weight: 289.2. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: Methanol: 20 mg/mL. lambdamax: 232 nm. SMILES: ClC1(Cl)CC1C2=CC=C(C=C2)OC(C)(C(O)=O)C. InChi Code: InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17). InChi Key: KPSRODZRAIWAKH-UHFFFAOYSA-N.